Barbara Kosacz - 30 May 2025 Form 4 Insider Report for Athira Pharma, Inc. (ATHA)

Role
Director
Signature
/s/ Mark Worthington, Attorney in fact for Barbara Kosacz
Issuer symbol
ATHA
Transactions as of
30 May 2025
Net transactions value
$0
Form type
4
Filing time
03 Jun 2025, 17:33:09 UTC
Previous filing
23 May 2025
SEC
View on sec.gov

Sponsored

Quoteable Key Fact

"Barbara Kosacz filed Form 4 for Athira Pharma, Inc. (ATHA) on 03 Jun 2025."

Quick Takeaways

  • This page summarizes Barbara Kosacz's Form 4 filing for Athira Pharma, Inc. (ATHA).
  • 1 reported transaction and 1 derivative row are listed below.
  • Filing timestamp: 03 Jun 2025, 17:33.

What Changed

  • Previous filing in this sequence was filed on 23 May 2025.
  • Current net transaction value: $0.

Why This Matters

  • This tells you what this filing adds before you inspect full transaction and derivative tables.
  • You can trace every row back to the original SEC filing document.

Official SEC Source

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

See Original Filing

Reporting Owners (1)

Name Relationship Address Signature Signature date CIK
Kosacz Barbara Director C/O ATHIRA PHARMA, INC., 18706 NORTH CREEK PARKWAY, SUITE 104, BOTHELL /s/ Mark Worthington, Attorney in fact for Barbara Kosacz 03 Jun 2025 0001763316

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction ATHA Stock Option (Right to Buy) Award $0 +20,900 $0.000000 20,900 30 May 2025 Common Stock 20,900 $0.3125 Direct F1
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The shares subject to the option will vest on the earlier of (i) May 30, 2026, or (ii) the day immediately before the date of the next annual meeting of the Issuer's stockholders that occurs after May 30, 2025. The option reported was granted pursuant to the terms of the Issuer's Outside Director Compensation Policy.

Sponsored